Loading
SP
Sonoma Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Miller Robert E, was filed 14 Mar 2018.
Sonoma Pharmaceuticals, Inc.: what insiders have been doing
Sonoma Pharmaceuticals, Inc. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). No insider at Sonoma Pharmaceuticals, Inc. has published a filing in the past twelve months. The most recent one dates from 21 June 2024.
Our records for Sonoma Pharmaceuticals, Inc. go back to 2016, with 26 purchases and no sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 March 2026 lists revenue at 19.5 m USD and net income at -3.2 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
93
Thresholds
n/a
Buy Volume
€114,784
26 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -74.2%Entry US$696.60 · Close at T+365 US$180.00
- -73.3%Entry US$729.00 · Close at T+365 US$194.40
- -61.9%Entry US$930.60 · Close at T+365 US$354.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,209 of 26,289 companies
14.2
score / 100
Value3
Quality25
FCF yld-77%
Earn yld-59%
EV/EBITDA·
ROE-43%
Gross mgn38%
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$1.12
Analyst consensus
Income statement
RevenueUS$19.5M
Gross profitUS$7.4M38% margin
EBITDA-US$2.3M-12% margin
Net income-US$3.2M-10.3% margin
Valuation
P/Book0.8x
Beta1.30
Balance sheet & cash
Market capUS$5.4M
Total debtUS$842k
Free Cash Flow-US$4.1M
Debt / Equity11%
Profitability & ownership
ROE-42.5%
ROA-5.4%
% insiders0.4%
% institutions2.3%
Last declaration on 21 June 2024
Declarations93 total
53,586 sharesCommon Stock, $0.0001 par valueSEC:0001683168-24-004425:0
53,586 sharesCommon Stock, $0.0001 par valueSEC:0001683168-24-004426:0
53,586 sharesCommon Stock, $0.0001 par valueSEC:0001683168-24-004424:0
15,000 sharesCommon Stock, $0.0001 par valueSEC:0001683168-24-004423:0
100,000 sharesCommon Stock, $0.0001 par valueSEC:0001683168-23-004632:0
100,000 sharesCommon Stock, $0.0001 par valueSEC:0001683168-23-004631:0
2,609 sharesCommon Stock, $0.0001 par valueSEC:0001683168-20-001273:0
3,086 sharesCommon Stock, $0.0001 par valueSEC:0001683168-20-001272:0
1,052 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-001578:0
1,538 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-001579:0
1,781 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-001580:0
1,200 shares@ US$4.105.5% of flowCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000672:1
Canonical exit: 11 Jun 2018 (T+90)
1,200 shares@ US$3.905.3% of flowCommon Stock, $0.0001 par vlue per shareSEC:0001683168-18-000658:0
Canonical exit: 7 Jun 2018 (T+90)
1,200 shares@ US$4.035.4% of flowCommon Stock, $0.0001 par vlue per shareSEC:0001683168-18-000658:1
Canonical exit: 10 Jun 2018 (T+90)
2,473 shares@ US$3.9915.6% of flowCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000628:0
Canonical exit: 6 Jun 2018 (T+90)
1,691 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000571:0
1,958 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000569:0
1,157 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000573:0
1,424 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000575:0
17,211 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000038:0
17,211 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000040:0
17,211 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000036:0
25,817 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000037:0
17,211 sharesCommon Stock, $0.0001 par value per shareSEC:0001683168-18-000039:0
345 shares@ US$4.952.8% of flowCommon Stock, $0.0001 par value per shareSEC:0001683168-17-003218:0
Canonical exit: 28 Feb 2018 (T+90)
25 of 93 declarations
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. is a company focused on developing pharmaceutical products for the treatment of skin diseases. It is listed on the NASDAQ under the symbol SNOA.
